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REVIEW TOPIC OF THE WEEK

Overcoming the Roadblocks to Cardiac
Cell Therapy Using Tissue Engineering
Mounica Yanamandala, MD,a Wuqiang Zhu, MD, PHD,b Daniel J. Garry, MD, PHD,c Timothy J. Kamp, MD, PHD,d
Joshua M. Hare, MD,e Ho-wook Jun, PHD,b Young-sup Yoon, MD, PHD,f Nenad Bursac, PHD,g
Sumanth D. Prabhu, MD,h Gerald W. Dorn II, MD,i Roberto Bolli, MD,j Richard N. Kitsis, MD,a Jianyi Zhang, MD, PHDb

ABSTRACT
Transplantations of various stem cells or their progeny have repeatedly improved cardiac performance in animal models
of myocardial injury; however, the beneﬁts observed in clinical trials have been generally less consistent. Some of the
recognized challenges are poor engraftment of implanted cells and, in the case of human cardiomyocytes, functional
immaturity and lack of electrical integration, leading to limited contribution to the heart’s contractile activity and
increased arrhythmogenic risks. Advances in tissue and genetic engineering techniques are expected to improve the
survival and integration of transplanted cells, and to support structural, functional, and bioenergetic recovery of
the recipient hearts. Speciﬁcally, application of a prefabricated cardiac tissue patch to prevent dilation and to
improve pumping efﬁciency of the infarcted heart offers a promising strategy for making stem cell therapy a
clinical reality. (J Am Coll Cardiol 2017;70:766–75) © 2017 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

A

lthough transplanted cells and engineered

with human-derived tissues or other xenogeneic

tissues result in improved cardiac perfor-

transplantation

mance when tested in animal models of

surviving cells rarely produce grafts of substantial

myocardial injury, the beneﬁts observed in clinical

size and may remain electrically isolated from the

trials have generally been modest at best. Opinions

native myocardium, which would prevent the graft

regarding the optimal cell type or combination of

from contributing to the contractile activity of the

cell types have yet to reach consensus, and only a

heart and, more importantly, could lead to arrhyth-

very small proportion of the administered cells are

mogenic complications, which may be the primary

engrafted by the native myocardium. Cellular attri-

safety concern associated with transplanted myocar-

tion is often attributed to a lack of perfusion in the

dial cells and tissues. Tissue engineering strategies

infarcted region, but the recipient’s immune system

are expected to improve engraftment of transplanted

may also play a role, particularly in preclinical studies

cells,

as

well

experiments.

as

structural,

Furthermore,

functional,
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bioenergetic recovery of the infarcted heart. These

than when the CMs were omitted (17).

ABBREVIATIONS

and many other topics were discussed by attendees

Furthermore, extracellular matrix production

AND ACRONYMS

of the National Institutes of Health 2016 Progenitor

in tissue-engineered patches appears to in-

Cell Biology Consortium and Cardiovascular Tissue

crease in response to production of trans-

Engineering Symposium at the University of Ala-

forming growth factor b1 by CMs (18,19), and

bama, Birmingham, on March 28, 2016. Here, we pre-

CMs are an important source of vascular

sent some of the more provocative ideas and

endothelial growth factor in cell sheet–based

advances that were discussed at the meeting and

engineered tissues (20). Thus, CMs and cy-

that may facilitate the translation of cardiac cell-

tokines that mediate CM–non-CM communi-

and tissue-engineering therapies from the laboratory

cation

to the clinic.

beneﬁcial activity induced by transplanted

are

crucial

components

of

the

engineered cardiac tissues.

CELL TYPES FOR USE IN CARDIAC THERAPY

CM = cardiomyocyte
CPC = cardiac progenitor cell
Cx43 = connexin 43
EC = endothelial cell
hiPSC = human induced
pluripotent stem cell

HLA = human leukocyte
antigen

hPSC = human pluripotent
stem cell

Other cell sources of potential utility for

MHC = major

cardiac repair include mesenchymal stem

histocompatibility complex

A wide variety of cell sources have been evaluated for

cells

MI = myocardial infarction

repair of the ischemic myocardium in animal models,

barrow), cardiac stem cells, cardiospheres

and a subset of these have undergone testing in

isolated from endocardial biopsies (in mice

clinical trials. A recent review by Nguyen et al. (1)

and humans), which are composed of a

summarized the clinical trials on stem cell therapy

heterogeneous cell population, but are exceptionally

for ischemic heart diseases and heart failure from

proliferative, and Abcg2-expressing progenitor cells

January 1, 2000, to July 2016. Table 1 adds the new

(21). When suspended in saline and transplanted into

clinical trials for ischemic heart diseases and heart

the hearts of mice after an acute infarction, Sca-1 þ/

failure published between July 27, 2016, and May 18,

CD31 cells appear to attenuate decline in cardiac

2017, based on our PubMed search results, as well as

function, increase myocardial neovascularization,

clinical trials for stem cell therapy for congenital

and modestly promote CM differentiation from graft

heart diseases.

cells, as well as host cell proliferation (22).

(prototypically

derived

from

bone

PSC = pluripotent stem cell
TNF = tumor necrosis factor

Human pluripotent stem cells (hPSCs) and newer

Variation of interspecies responses to cell therapy

cell types, such as induced cardiac progenitor cells

is another critical issue. Commonly used preclinical

(CPCs) (2,3), are especially promising for cardiac cell

models include nonhuman primates, large mammals

and tissue engineering therapy (4–6) because they

(swine, dog, and others), and rodents. Although it

can be efﬁciently differentiated into functional car-

might be necessary, there is neither guidance on

diomyocytes (CMs), endothelial cells (ECs), and

selection of preclinical animal models nor consensus

smooth muscle cells (SMCs) (7–11). However, the

criteria

optimal proportions of each cell type have yet to be

studies thus far. Genetic background may affect the

on

experimental

design

for

preclinical

identiﬁed, and a variety of other cell lineages (e.g.,

interpretation of experimental results. Therefore,

resident CPCs) (12) may be needed to maximize

comparison and validation of data collected from

therapeutic effectiveness. Furthermore, mitochon-

different species are important when translating

dria have important functions in cardiac metabolism

preclinical research to clinical trials.

(13) and programmed CM death (14), and emerging
roles

in

cardiac
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differentiation

were

Although transplantation of various cell types has

recently

been reported to improve left ventricular function

suggested (15,16). Speciﬁcally, CM differentiation

and structure after MI, overwhelming evidence has

requires the membranes of adjacent mitochondria to

demonstrated that there is no signiﬁcant long-term

fuse, and fusion of the outer membranes is regulated

engraftment of adoptively transferred cells into the

by mitofusins 1 and 2, which direct ESC differentia-

host myocardium. The persistence of beneﬁcial

tion into CMs via regulation of calcineurin and Notch

effects, despite the disappearance of transplanted

signaling (16).

cells, indicates that cell therapy may act via paracrine

The importance of restoring functional CMs for

mechanisms. In addition, the rapid clearance of cells

post-infarction repair is self-evident because they

from the host myocardium suggests that the beneﬁts

provide the mechanical force needed for contraction.

of cell therapy are limited by the poor engraftment of

In a rat model of myocardial infarction (MI),

the cells, implying that 1 dose does not adequately

measurements of cardiac function and remodeling

test the efﬁcacy of that cell product (23). However,

were signiﬁcantly better when implanted ﬁbrin gel-

almost all preclinical and clinical studies of cell

based tissue-engineered patches were created from

therapy performed heretofore have based their

the complete population of neonatal rat cardiac cells

assessment

of

efﬁcacy

on

the

outcome

of

768
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T A B L E 1 Published Stem/Progenitor Cell Clinical Trials for Heart Diseases

Diseases

Trial Design

HLHS

Nonrandomized (phase 1)

HLHS

Randomized (phase 2)

Sample Size

Cell Type

Cell Source

Delivery Route

7

Autologous CDC

Cardiosphere

IC

34

Autologous CDC

Cardiosphere

IC

Ischemic heart disease

Randomized control (phase 2)

90

Autologous BMCs

Bone marrow

IC vs. IM

Ischemic heart disease

Randomized control (phase 3)

271

Autologous MSCs

Bone marrow

IM

Nonischemic cardiomyopathy

Randomized control (phase 2)

22

Allogeneic MSCs

Bone marrow

IV

Refractory angina

Randomized control (phase 2)

31

Autologous CD133þ cells

Bone marrow

TEP

Nonrandomized (phase 1)

27

Autologous skeletal
stem-cell sheets

Randomized (phase 2)

37

Allogeneic MSC (19 patients) vs.
autologous MSC (18 patients)

Bone marrow

TEP

Autologous BMCs

Bone marrow

IC

Ischemic vs. nonischemic
dilated cardiomyopathy
Nonischemic dilated
cardiomyopathy
STEMI

Randomized control (phase 2)

188

Skeletal muscle
(vastus medialis)

Sutured to
heart surface

BMC ¼ bone marrow–derived cell; BNP ¼ B-type natriuretic peptide; CDC ¼ cardiosphere-derived cells; HLHS ¼ hypoplastic left heart syndrome; hMSC ¼ human mesenchymal stem cell; IC ¼ intracoronary
infusion; IM ¼ intramyocardial injection; IV ¼ intravenous; LVEF ¼ left ventricular ejection fraction; MSC ¼ mesenchymal stem cell; NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; RVEF ¼ right
ventricular ejection fraction; STEMI ¼ ST-segment elevation myocardial infarction; TEP ¼ transendocardial injection; TNF ¼ tumor necrosis factor.

1 administration of a cell product. The problem of

engraftment and survival of transplanted cells is to

modest or no beneﬁcial effects might be overcome by

use natural or artiﬁcial biomaterials that provide a

repeated cell doses. The rationale is that just as most

protective environment for the transplanted cells

pharmacological agents are ineffective when given

(28–30). Overall, published reports indicate that the

once, but can be highly effective when given repeat-

functional beneﬁts of the cardiac cell patch therapy

edly, a cell product might be ineffective or modestly

critically depend upon the longer-term structural

effective as a single treatment, but might be quite

integrity of the cell patches. Maintenance of longer-

efﬁcacious if given repeatedly.

term graft size remains a major challenge in preclin-

On the basis of preclinical data performed in large

ical trials of cell therapy.

animal models, human testing of various adult cell
sources has progressed from phase I to phase III trials

IMMUNOGENICITY

(24,25). From a mechanistic standpoint, cell therapy
in the iterations described earlier reduces tissue

One of the chief beneﬁts of human induced pluripotent

ﬁbrosis, restores tissue perfusion, has a powerful

stem cells (hiPSCs) is that they can be generated from a

anti-inﬂammatory effect, and stimulates myogenesis,

patient’s own somatic cells, and consequently are not

largely by promoting endogenous myogenesis (24).

expected to provoke an immune response after trans-

Moreover, clinical trial activity is extending into

plantation. Although this approach holds appeal for

numerous cardiomyopathic disease states, including

avoiding pharmacological immunosuppression and

hypoplastic left heart syndrome, adriamycin-induced

associated complications, it requires a substantial time

cardiomyopathy, and idiopathic dilated cardiomyop-

window (months) for hiPSC generation, followed by

athy. Future efforts to apply tissue-engineering

differentiation and graft formation. Thus, this autol-

strategies

ogous approach is better suited to treatment of more

in

the

clinical

setting

will

emerge

following appropriate preclinical testing.

chronic heart failure with existing technology. However, some studies suggest that the immune tolerance

CELL ENGRAFTMENT

of patient-speciﬁc induced PSC–derived cells may vary

As many as 1 billion CMs are lost during MI, and

regarding immunogenicity are often addressed by

although the typical dose of transplanted cells may

performing experiments in mice with humanized im-

approach or exceed this number, just 0.1% to 10% of

mune systems, but the currently available models

the cells are engrafted into the myocardium and

have a limited lifespan and inconsistent immune

depending on the cells’ lineage (31–34). Questions

continue to survive for more than a few weeks after

response, perhaps because the animals’ endogenous

transplantation (26,27). Much of this attrition can be

immune system is eliminated with sublethal doses of

attributed to the harsh environment in and near the

radiation. Collectively, these observations suggest

region of the infarct; thus, one strategy for improving

that translation of hiPSC-derived cell technology to
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T A B L E 1 Continued

Summary/Observation
Follow-Up

Heart Function

18–36 months

[ RVEF
[ RVEF

12 months
6–12 months

Others

Trial Name/Identiﬁer

Improved somatic growth

[ LVEF in IM group, but not in IC group

TICAP/NCT01273857 (78,79)

Reduced ﬁbrosis, improved somatic growth

PERSEUS/NCT01829750 (80)

YNT-proBNP in IM group, but not IC group

REGENERATE-IHD/NCT00747708 (81)

39 weeks

No change LVEF

Y incidence of sudden or aborted sudden deaths

90 days

No change LVEF

[ health status and Y circulating inﬂammatory cells

NCT02467387 (83)

1, 4, 6, and 12 months

No change LVEF

Y angina

REGENT-VSEL/NCT01660581 (84)
UMIN000003273 (85)

12 months

[ LVEF in patients with ischemic heart
diseases, but not in patients with
nonischemic heart diseases

Y BNP in patients with ischemic heart diseases, but
not in patients with nonischemic heart diseases

12 months

[ LVEF in allo-MSC group, but not in the
auto-MSC group

Y TNF-a, to a greater extent with allo-hMSCs vs.
auto-hMSCs at 6 months

6 months

[ LVEF in BMC group

No treatment effect in irradiated BMC group

CHART-1/NCT01768702 (82)

POSEIDON-DCM/NCT01392625 (24)
BOOST-2/ISRCTN17457407 (86)

clinical applications will likely require testing of the

be used to treat a wider variety of patients and

immunogenicity of each hiPSC-derived cell lineage in a

diseases.

new generation of models that can provide more

IMMUNOMODULATION

consistent and reliable results.
Allograft

rejection

is

primarily

mediated

by

host-derived reactive T lymphocytes that recognize

As described earlier, stem cell engraftment rates and

non-self human leukocyte antigens (HLAs) on the

survival following transplantation are disappoint-

surface of transplanted donor cells. Humans have 2

ingly low. Moreover, among surviving transplanted

main categories of HLAs: major histocompatibility

progenitor cells, the demonstrable magnitude of dif-

complex (MHC) classes I and II. The Townes laboratory

ferentiation into functional CMs has been variable,

recently showed that surface expression of HLA class I

ranging from no evidence of CM differentiation to

molecules can be largely eliminated in a line of human

generation of small, apparently integrated CMs

embryonic stem cells (H9) using the clustered regu-

(22,26,37–39). Most studies of cell therapy seek to

larly interspaced short palindromic repeats (CRISPR)/

intervene therapeutically either after MI or during

CRISPR-associated protein (Cas) gene-editing system

chronic heart failure. The proinﬂammatory environ-

to knock out both alleles of the gene for b2 micro-

ment of the failing heart may also be responsible for

globulin, which is essential for cell-surface expression

the reported functional beneﬁts of cardiac cell ther-

of HLA class I and stability of the peptide-binding

apies. As both of these pathological scenarios exhibit

groove. CRISPR/Cas gene editing has also been used

heightened inﬂammatory activation and innate and

to knock out the Class II MHC transactivator (CIITA) in

adaptive immune cell inﬁltration in the myocardium

human ECs, and the CIITA-knockout ECs could be

(40–43), these microenvironmental factors may be

transplanted into mice without producing an immune

important contributors to the suboptimal responses

response (35). The degree of differentiation of the

to cell therapy. For example, tumor necrosis factor

hiPSCs derivatives engrafted may also inﬂuence the

(TNF), a proinﬂammatory cytokine elaborated by

immunogenicity of the tissue grafts. This is particu-

both immune cells and failing CMs, restrains CM dif-

larly relevant for tissue-engineering applications,

ferentiation of resident cardiac stem cells, and can

because even when professional antigen-presenting

channel

cells are depleted, cell-mediated allograft rejection

in vitro (44); these effects would be expected to

can still occur (36). This is perhaps because human ECs

diminish the reparative effects of stem cell therapy.

activate alloantigen-reactive memory CD4 þ T cells via

Such ﬁndings suggest that immunomodulation of the

a mechanism requiring expression of class II MHCs.

proinﬂammatory microenvironment in recipients of

Thus,

enable

progenitor cell therapy may be a high-yield strategy

researchers to create “universal donor” hiPSC lines, as

to enhance cell engraftment and CM differentiation.

well as hiPSC-derived cells and engineered tissues

To date, such approaches have been relatively unex-

with substantially higher rates of engraftment that can

plored, but could include targeting speciﬁc innate

gene-editing

technologies

may

an

alternate

neuroadrenergic-like

fate
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and

primarily through the gap-junction proteins connexin

proinﬂammatory macrophages), speciﬁc cytokines

immune

cell

40, connexin 43 (Cx43), and connexin 45 (48), of

(e.g.,

T-cell

which Cx43 is by far the most abundant. Cx43 is

responses. These methodologies would be comple-

expressed in both atrial and ventricular myocytes

mentary to the suppression of antigen-dependent

(49), and deﬁciencies in Cx43 expression or organi-

MHC responses described earlier, and would ideally

zation have been linked to development of arrhyth-

comprise circumscribed interventions designed to

mias in patients with heart failure and other

improve cell engraftment at the time of delivery and

cardiomyopathies (48,50,51). Furthermore, previous

subsequent CM differentiation during initial repair.

studies (52) suggested that the risk of arrhythmogenic

Interestingly, mesenchymal stem cells suppress TNF

complications from transplanted cells may decline

TNF),

populations
and/or

(e.g.,

inﬁltrating

antigen-independent

levels substantially, and this effect may therefore

substantially if the cells were genetically modiﬁed to

contribute to some of the positive effects of these

overexpress Cx43. Thus, graft-associated arrhythmo-

cells in clinical trials (24).

genicity may be substantially reduced by using
gene-editing technologies to increase expression of

ARRHYTHMOGENESIS

gap-junction

Injected hPSC-derived CMs have not been associated

and immature expression and distribution of ion

with arrhythmias in rodents, but when the dose was

channels and gap junctions in transplanted CMs, as

scaled

primates

well as the isotropic architecture of the grafts, likely

(macaques), all 4 of the cell-treated animals experi-

contributed to the occurrence of arrhythmias in ma-

enced periods of premature ventricular contractions

caques, despite proven host–graft Cx43 coupling

and/or ventricular tachycardia (45). These results

(30,46). Additional experimental and computational

were recently conﬁrmed in a larger set of macaques

studies are warranted to establish critical structural

upon allogeneic transplantation of macaque PSC-

and functional properties of transplanted grafts

derived CMs suspended in a prosurvival cocktail

leading to increased arrhythmia susceptibility.

up

for

delivery

proteins

in

transplanted

CMs

or

surrounding nonmyocytes. Still, the small cell size

to

nonhuman

(46). The discrepancy between observations in rodents and macaques may have occurred because the

Furthermore, the results from a recent study (53)
suggest

that

intramyocardially

injected

cardiac

large dose of cells administered to macaques was

microtissue particles (consisting of w1,000 cells/

accompanied by a dramatic ($10-fold) increase in

particle) suspended in prosurvival cocktail produce

tissue graft size. As the action potential passes

grafts that are electrically coupled to the native

through the myocardium, the anatomic and/or func-

myocardium, but an epicardially implanted engi-

tional heterogeneity introduced by these large re-

neered cardiac tissue patch does not. The combined

gions of immature, electrically active tissue may slow

use of genetically encoded ﬂuorescent calcium

down or partially block conduction, thus setting the

reporters (e.g., GCaMP) (45,46) targeted to trans-

conditions for life-threatening re-entrant arrhythmias

planted

(47). Because they are electrically immature and

nonoverlapping

contain sinoatrial nodal cells, hPSC CMs possess

myocardial tissue will be valuable for exploring the

autonomous pacemaking activity and consequently,

mechanisms of arrhythmogenesis and evaluating the

are capable of ectopic beats that could further pre-

effectiveness of strategies for improving electrome-

cipitate arrhythmia induction. If exogenous cells

chanical integration of engineered myocardial grafts.

cells

and

voltage-sensitive

emission

spectra

dyes

with

labeling

host

indeed engraft at much higher rate, this may result in
even more severe ventricular arrhythmias. Of note,

MYOCARDIAL BIOENERGETICS

compared with human hearts, macaque hearts are
much smaller and their resting rate is much higher,

The contractile activity of engineered myocardial tis-

which raises doubts as to their suitability for pre-

sue is expected to contribute directly to myocardial

dicting arrhythmogenic risks in humans. Although

performance, but improvements can also evolve

larger animals, such as pigs, are a better model of

through the release of cytokines that promote angio-

human heart physiology, objective assessment of

genesis, activate endogenous progenitor cells (20,54),

human cell therapies in large animals will require

or stimulate other beneﬁcial paracrine pathways.

adequate immunosuppression, which may be easiest

Furthermore, the damage induced by an acute infarct

to achieve in nonhuman primates.

event is exacerbated by chronic myocardial overload,

In adult mammalian hearts, electrical propagation
and

myocardial

contractions

are

coordinated

dilation, and overstretching, which increase wall
stress and can lead to metabolic abnormalities, such
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as declines in the rate of adenosine triphosphate

injury (22,63), but the regenerative capacity of adult

(ATP) use or in the ratio of phosphocreatine to ATP

mouse and human hearts is much more limited.

in surrounding CMs (55–58). These bioenergetic ab-

Nevertheless, studies that map cell fate or use

normalities were largely corrected when hiPSCs were

radiocarbon dating indicate that both murine and

differentiated into hiPSC-ECs and hiPSC-SMCs, and

human CMs are continually replaced, albeit at a very

then suspended in a ﬁbrin scaffold positioned over the

low rate: an average of w1% of human CMs are newly

site of infarction in swine hearts (55). Thus, a consid-

formed each year, with roughly one-half of the cells

erable

with

replaced over a lifetime (59,64). A number of studies

engineered tissue transplantation may stem from the

indicate that adult hearts can be remuscularized

structural support of the graft or its cytokine produc-

through the proliferation and differentiation of c-Kitþ

tion, in addition to direct remuscularization of the

CPCs, and endogenous CPCs may also release exo-

injured region.

somes or paracrine factors that modulate the repair

amount

of

the

beneﬁt

associated

process and promote neovascularization. Neverthe-

ENGINEERED ORGANS

less, genetic fate-mapping assessments by van Berlo
et al. (65,66) indicated that although c-Kitþ CPCs can

Current limitations of human organ transplants have

give rise to CMs, they do so in an extremely limited

prompted researchers to consider use of xenogeneic

fashion. Newly emerging studies are showing that

organs as an alternative strategy. For example, func-

endogenous repair mechanisms can be dramatically

tional pancreatata composed of rat cells have been

up-regulated (67).

generated in mice by injecting murine blastocysts

Furthermore,

although

the

ﬁbroproliferative

with rat PSCs (59), and then transplanting the blas-

response (i.e., scar formation) is beneﬁcial for short-

tocysts into surrogate mouse dams. Importantly, the

term stability at the injury site, it interferes with

blastocysts could not generate the target organ

subsequent repair processes, such as vascular growth

because they expressed a mutated form of Pdx1, the

and potentially remuscularization. Thus, researchers

master regulatory gene for pancreatic development,

have also begun to investigate methods for control-

and consequently provided a niche for the develop-

ling or reverting ﬁbrosis by reprogramming ﬁbro-

ment of the wild-type rat organ. This “blastocyst

blasts into CMs or ECs (68–70), and by identifying the

complementation” strategy has also been used to

cellular source(s) contributing to scar formation

produce livers and kidneys in rodents and pan-

(71,72). The use of tissue-engineered systems may

creatata in pigs (60–62), whereas members of the

increase in vitro efﬁcacy and improve understanding

Garry laboratory used an analogous approach that

of

combined gene editing with somatic cell nuclear

(73,74), as well as permit well-controlled mechanistic

transfer to engineer pig embryos that lacked cardio-

studies of CM/nonmyocyte interactions (75).

the

direct

cardiac

reprogramming

processes

vascular cells, and then rescued this deﬁciency with
wild-type, green ﬂuorescent protein–labeled pig

DISPARITY BETWEEN PRECLINICAL

blastomeres. Although these studies support the

AND CLINICAL STUDY RESULTS

feasibility of generating patient-speciﬁc organs that
can be used as models for preclinical work or,

The positive results from studies of cell therapy for

perhaps, as organs for transplantation therapy, the

the treatment of MI in small-animal models have

utility of this technology will remain limited until

generally not been observed in clinical trials. For

methods for generating organs from human stem cells

example, results from a phase I clinical trial indicated

become more efﬁcient.

that although intracoronary administration of autologous cardiac sphere-derived stem cells associated with

STIMULATING ENDOGENOUS

a signiﬁcantly decreased infarction size in patients

REGENERATION AND REPAIR

with acute MI, left ventricular chamber function did
not improve (76). Many of the factors that determine

In addition to transplantation of exogenous stem cells

the effectiveness of cell- or engineered-tissue–based

and engineered tissues or organs, the ability to

therapies likely depend both on the unique charac-

stimulate endogenous cardiac repair could eventually

teristics of each speciﬁc disease state and on complex

lead to development of effective cell-free therapies

interactions among numerous mechanisms of action,

for MI. Lower organisms, such as the newt and

but these variables cannot be adequately or safely

zebraﬁsh, as well as neonatal mice, have a tremen-

explored in clinical investigations. Future tissue-

dous ability to regenerate from severe myocardial

engineering therapies for MI are expected to face the
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The delivery of types of cells generally resulted in modest therapeutic beneﬁts. Transplantation of pre-fabricated engineered heart tissue (e.g., cardiac tissue patch
containing pluripotent stem cell–derived tri-cardiac cells) could enhance the therapeutic effects by an increased engraftment rate, which in turn, results in prolonged
release of cytokines, reduction in left ventricular (LV) dilation and LV wall stresses. A major challenge that remains to be addressed is the potential arrhythmia
risks associated with a large graft.

same logistic issues. Thus, relevant large-animal

CONCLUSIONS

models of myocardial dysfunction are critical for
identifying,

the

Although adult bone marrow– or myocardium-derived

physiological response to cell and tissue trans-

characterizing,

and

quantifying

progenitors can offer multiple paracrine beneﬁts to

plantation therapies, as well as the optimal cell or

surviving CMs in the infarcted heart, they are unlikely

biomaterial type, dose, timing, and route of adminis-

to contribute to the formation of de novo working

tration, to ensure that each patient receives the

myocardium (77). CMs derived from PSCs can address

maximum possible beneﬁt while avoiding the com-

this challenge, but are more complicated to use in

plications associated with overtreatment.

autologous therapies and potentially less robust to
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surviving transplantation. Although the jury for the

Major challenges will be to address the potential

optimal cell source is still out, it is possible that

arrhythmogenicity risks associated with a large graft.

different disease applications will require different

With exciting translational prospects ahead, future

cell types, and that a mixture of immune-matched or

studies to optimize engineered cardiac tissue thera-

immune-engineered PSC-derived CMs and host-

pies in large animals and decipher the mechanisms of

derived stromal progenitors will prove optimal in

action are fully warranted.

inducing heart remuscularization while supporting
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